Home Business India kicks off massive Covid-19 vaccination drive on Saturday, Jan. 16

India kicks off massive Covid-19 vaccination drive on Saturday, Jan. 16

Bangalore Airport workers transfer carton boxes containing vials of Covishield vaccine developed by the Serum Institute of India in Bangalore, India, Jan. 12, 2021.

Stringer | Xinhua | Getty Images

SINGAPORE — India is gearing up for one of the largest mass vaccination exercises in the world starting Saturday.

The South Asian country plans to inoculate some 300 million people, or more than 20% of its 1.3 billion population, against Covid-19 in the first phase of the exercise.

Indian airlines have started delivering the first doses of vaccines to Delhi and other major cities, including Kolkata, Ahmedabad and tech hub Bengaluru, tweeted Civil Aviation Minister Hardeep Singh Puri earlier this week.

Priority for the shots will be given to health-care and other frontline workers — an estimated 30 million people. That would be followed by those above 50 years of age and other younger, high-risk individuals.

The rollout will involve close collaboration between the central government and states.

India has also developed a digital portal called Co-WIN Vaccine Delivery Management System. It will provide real-time information on “vaccine stocks, their storage temperature and individualized tracking of beneficiaries,” according to the health ministry.

India has a long history of immunization campaigns … and will rely on this expertise to distribute coronavirus vaccines.

“India’s expertise in vaccine manufacturing and experience with mass immunization campaigns has prepared it well for ‘phase 1’ vaccinations set to begin this weekend,” Akhil Bery, South Asia analyst at Eurasia Group, wrote in a report this week.

“India has a long history of immunization campaigns, including its Universal Immunization Program that inoculates 55 million a year, and will rely on this expertise to distribute coronavirus vaccines,” he added.

Emergency approval

India’s drug regulator has approved the restricted use of two coronavirus vaccines in emergency situations, both of which are being delivered to the various inoculation centers ahead of Saturday.

One of them is a vaccine developed by British-Swedish firm AstraZeneca and Oxford University, which is being manufactured domestically by the Serum Institute of India (SII) and is known locally as Covishield.

Another vaccine, called Covaxin, was developed domestically by India’s Bharat Biotech in collaboration with the state-run Indian Council of Medical Research. It was granted emergency use authorization as clinical trials continue.

The approval of Covaxin was reportedly criticized by some as the regulator gave the green light shortly after asking Bharat Biotech for more analysis.

India’s health secretary on Tuesday said the Indian government has signed procurement agreements for 11 million doses of Covishield at 200 Indian rupees ($2.74) per dose and 5.5 million doses of Covaxin at an average cost of 206 rupees per shot, which is likely to be cheaper than what they will cost in the private market.

Several other candidates, including a second domestically developed vaccine by Zydus Cadila, are undergoing clinical trials.

Potential risks

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Biden plans blitz of executive action in first 10 days

President-elect Joe Biden plans to take immediate executive action to turn the page on the Trump era after his inauguration speech this week, chief...

Akshay Kumar donates for construction of Ram Temple in Ayodhya, asks fans to contribute

After announcing his film ‘Ram Setu’ on Diwali 2020, the actor met U.P. Chief Minister Yogi Adityanath in Mumbai in December. Actor Akshay Kumar...

Recent Comments